Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.46 |
| ▸ | ATAD2 | Q6PL18 | 5/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | BPTF | Q12830 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | IDH2 | P48735 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082185 | 0.86 | RXFP1 (0.40) | RXFP1 | |
| SCHEMBL8567454 | 0.81 | ITK (0.48) | BRD4ATAD2CHEK1ITK | |
| SCHEMBL4552186 | 0.81 | RXFP1 (0.39) | BRD4RXFP1 | |
| SCHEMBL1053066 | 0.76 | BRD4 (0.44) | BRD4ATAD2 | |
| SCHEMBL1054261 | 0.71 | BRD4 (0.47) | BRD4ATAD2CHEK1JAK1 | |
| SCHEMBL4291997 | 0.71 | BRD4 (0.47) | BRD4ATAD2CHEK1JAK1 | |
| SCHEMBL23830542 | 0.70 | SLC6A2 (0.44) | — | |
| SCHEMBL4300332 | 0.70 | ITK (0.47) | BRD4ATAD2ITK | |
| SCHEMBL1081106 | 0.70 | CA12 (0.52) | RXFP1 | |
| SCHEMBL4553278 | 0.68 | CA12 (0.37) | RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875624-B2 | administering a cancer patient 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one in the treatment of disorders relating to cell adhesion and metastatic processes; for monitoring the effects of drug by measuring the levels of ICAM, VCAM, or E-selectin in the patient | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | CHIRON CORPORATION | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | BRD4 697/4885ATAD2 2615/4885CHEK1 2358/4885 |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | VCAM1, EPCAM, ICAM1 | BRD4 2641/4885ATAD2 4534/4885CHEK1 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.